Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing companies
Screener
Sort
Stage
Indication
Market Cap
Price
Short ratio
Relative Volume
Price to book
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
$107.54
+1.44  +1.36%
1.8 billion
$189.8 billion
04/09/2021
Tap to view 63 drugs
Drug Indication Stage News
Botox Forehead lines Approved Approval (third indication) announced October 3, 2017.
Depatuxizumab mafodotin ABT-414 Glioblastoma (rGBM) Phase 3 Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017.
Atogepant Chronic migraine PDUFA NDA acceptance announced March 30, 2021. PDUFA date late-3Q 2021.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 data due 2021.
ABICIPAR Age-related macular degeneration (AMD) CRL CRL issued June 26, 2020.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Approved Approval announced June 11, 2018.
Venetoclax - CANOVA Relapsed or refractory multiple myeloma Phase 3 Phase 3 data due in 2021.
Risankizumab Psoriasis Approved FDA approval announced April 23, 2019.
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) Approved Approval announced August 2, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commenced 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib Atopic Dermatitis PDUFA PDUFA date early 3Q 2021. Three month extension announced April 2, 2021.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) Approved Approval announced August 3, 2017.
Elagolix Uterine Fibroids Approved FDA approval announced May 29, 2020.
Elagolix Endometriosis Approved FDA approval announced July 24, 2018.
Ubrogepant Migraine Approved FDA Approval announced December 23, 2019.
ABT-494 upadacitinib Rheumatoid arthritis Approved FDA Approval announced August 16, 2019.
Rova-T (TAHOE) Second-line Small Cell Lung Cancer Phase 3 Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU) First-line Small Cell Lung Cancer Phase 3 Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Approved FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib) Waldenström’s Macroglobulinemia Approved FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib) Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta First line unfit AML Approved FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE Ulcerative colitis Phase 3 Phase 3 trial met primary and secondary endpoints - December 9, 2020.
Venetoclax and obinutuzumab Chronic Lymphocytic Leukemia Phase 3 FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica) Pancreatic cancer Phase 3 Phase 3 primary endpoint not met (PFS/OS).
Venclexta BELLINI Multiple myeloma Phase 3 Phase 3 primary endpoint met.
Botox Lower limb spasticity Approved FDA Approval announced October 24, 2019.
Botox Upper limb spasticity Approved FDA Approval announced June 21, 2019.
Venetoclax and obinutuzumab Chronic lymphocytic leukemia sNDA Filing sNDA filing announced June 4, 2019.
Juvéderm VOLUMA Mid-Face Injection Via Cannula Approved FDA Approval announced September 3, 2019.
Veliparib Ovarian cancer Phase 3 Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS ) Psoriasis Phase 3 Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approved FDA Approval announced April 21, 2020.
Risankizumab vs secukinumab Plaque psoriasis Phase 3 Phase 3 trial met primary endpoint - January 14, 2020.
Upadacitinib Psoriatic arthritis PDUFA PDUFA date extended by three months to late-2Q 2021.
Risankizumab MOTIVATE Crohn’s Disease Phase 3 Phase 3 trial met primary endpoint - January 7, 2021.
Risankizumab KEEPSAKE2 Psoriatic Arthritis Phase 3 Phase 3 trial met primary endpoint - January 5, 2021.
Upadacitinib Atopic dermatitis Phase 3 Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020.
Venclexta (VIALE-A) Acute Myeloid Leukemia (AML) Approved FDA approval announced October 16, 2020.
Imbruvica + Venclexta (CAPTIVATE) Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Phase 2 Phase 2 trial ongoing.
Ibrutinib in combination with prednisone Chronic Graft Versus Host Disease Phase 3 Phase 3 trial ongoing.
ABBV-951 Parkinson's disease Phase 3 Phase 3 data due late-2021.
Ibrutinib COVID-19 Phase 2 Phase 2 trial has been initiated.
JUVÉDERM VOLUMA Augmentation of the chin region Approved FDA Approval announced June 15, 2020.
Botox Neurogenic Detrusor Overactivity Approved FDA approval announced February 10, 2021.
RINVOQ (upadacitinib) Active Ankylosing Spondylitis PDUFA sNDA filing announced August 25, 2020. PDUFA estimate June 25, 2020.
AGN-190584 Presbyopia NDA Filing NDA filing announced February 25, 2021.
Cariprazine (Vraylar) Major depressive disorder Phase 3 Phase 3 data due 2021.
Upadacitinib Ulcerative Colitis (induction/maintenance) Phase 3 Phase 3 data due 2021.
Upadacitinib Crohn's disease (induction/maintenance) Phase 3 Phase 3 data due 2021.
Imbruvica (SHINE) Mantle Cell Lymphoma Phase 3 Phase 3 data due 2021.
Imbruvica + Venclexta (GLOW) Chronic Lymphocytic Leukemia Phase 3 Phase 3 data due 2021.
$28.35
-2.24  -7.32%
269.5 million
$7.6 billion
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
BamlanivimabLY-CoV555 COVID-19 Antibody Approved Emergency Use Authorization (EUA) announced November 9, 2020.
$1.64
-0.03  -1.80%
98.8 million
$162 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
ABO-101 Sanfilippo syndrome type B (MPS IIIB) Phase 1/2 Phase 1/2 updated data announced February 12, 2021.
EB-101 - VITAL Recessive dystrophic epidermolysis bullosa (RDEB) Phase 3 Phase 3 enrollment to be completed in 2021.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 updated safety data released February 12, 2021. Well tolerated.
ABO-202 CLN1 disease (Infantile Batten disease) Phase 1/2 Phase 1/2 trial planned.
$3.63
+0.02  +0.55%
14.4 million
$52.3 million
04/09/2021
Tap to view 2 drugs
Drug Indication Stage News
Gencaro Chronic Heart Failure Phase 3 Phase 3 trial initiation on hold - dependent on obtaining additional financing.
AB201 COVID-19 Phase 2b Phase 2b top-line data due 3Q 2021.
$3.30
+0.01  +0.30%
96.7 million
$319.3 million
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
AB-452 Hepatitis B Phase 1 Program to be discontinued - February 10, 2020.
AB-506 Hepatitis B (HBV) Phase 1 Development to be discontinued - noted October 3, 2019.
AB-729 Hepatitis B (HBV) Phase 1 Phase 1a/b further data due 1H 2021.
AB-836 Hepatitis B Phase 1a Phase 1a/1b trial to be initiated 1H 2021.
AB-729 and vebicorvir Hepatitis B virus (HBV) Phase 2 Phase 2 trial initiation announced February 26, 2021.
$20.39
-0.29  -1.40%
160 million
$3.3 billion
04/09/2021
Tap to view 9 drugs
Drug Indication Stage News
Pimavanserin - CLARITY-2 and CLARITY-3 Adjunctive Treatment in Patients With Major Depressive Disorder Phase 3 Phase 3 trial did not meet primary endpoint - July 20, 2020.
Pimavanserin - Advance-2 Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 3 Phase 3 trial initiated 3Q 2020.
Pimavanserin - Enhance Adjunctive treatment of schizophrenia Phase 3 Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Announced October 4, 2017 that trial will be discontinued.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin Alzheimer’s disease psychosis CRL CRL announced April 5, 2021.
Trofinetide (LAVENDER) Rett Syndrome Phase 3 Phase 3 data due 4Q 2021.
ACP-044 Pain Phase 2 Phase 2 trial to be initiated 1H 2021.
XEN1101 Major depressive disorder Phase 2 Phase 2 trial to be initiated 2Q 2021.
$3.02
-0.05  -1.63%
14.3 million
$43.2 million
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
EDSIVO Vascular Ehlers-Danlos Syndrome CRL CRL issued June 25, 2019.
Tovaxin (Tcelna) Secondary Progressive MS (SPMS) Phase 2b Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001 Urea cycle disorder (UCD) NDA Filing Pre-NDA meeting with FDA due 2Q 2021 with NDA filing due mid-2021.
Osanetant induced Vasomotor Symptoms (iVMS) Phase 1/2 Phase 1/2 trial to be initiated 4Q 2021.
Emetine COVID-19 Phase 2/3 Phase 2/3 trial to be initiated 1H 2021.
$13.19
+0.31  +2.41%
19.6 million
$258.4 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
ADI-001 Non-Hodgkin’s lymphoma Phase 1 Phase 1 trial initiation announced March 10, 2021. Data due by end of 2021.
$13.78
-0.73  -5.03%
40.6 million
$559.8 million
04/09/2021
Tap to view 2 drugs
Drug Indication Stage News
ATL001 - CHIRON Non Small Cell Lung Cancer Phase 1/2 Phase 1/2 interim data due 2H 2022.
ATL001 - THETIS Melanoma Phase 1/2 Phase 1 interim data due 2H 2022.
$11.40
+0.15  +1.33%
6.1 million
$70.1 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
Cytisine - ORCA-2 Smoking cessation Phase 3 Phase 3 enrollment to be completed mid-2021.
$6.87
-0.04  -0.58%
72.7 million
$499.5 million
04/09/2021
Tap to view 8 drugs
Drug Indication Stage News
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab Alzheimer’s disease Phase 2 Phase 2 top-line data did not meet endpoints - September 23, 2020.
ACI-24 (anti-Abeta vaccine) Alzheimer's disease-like characteristics in individuals with Down syndrome Phase 1b Phase 1b presentation at AAIC July 26-30, 2021.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Semorinemab (LAURIET) Alzheimer’s disease Phase 2 Phase 2 primary completion 2Q 2021.
ACI-3024 Alzheimer’s disease Phase 1 Phase 1 trial has completed.
ACI-35.030 Alzheimer’s Disease Phase 1/2 Phase 1b/2a further interim data due 4Q 2021.
ACI-24 Alzheimer’s disease (AD) Phase 2 Phase 2 18-month analysis due 2Q 2021.
$4.19
-0.25  -5.63%
9.5 million
$39.8 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
Ampyra Improve walking in patients with multiple sclerosis Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Tozadenant Parkinson’s disease (PD) Phase 3 Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301) OFF episodes of Parkinson’s disease (PD) Approved FDA Approval announced December 22, 2018.
$28.96
-0.13  -0.45%
51.8 million
$1.5 billion
04/09/2021
Tap to view 7 drugs
Drug Indication Stage News
ATI-502 (ATI-50002-AA-201) - dose ranging Alopecia areata Phase 2 Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical) Vitiligo Phase 2 Development to be discontinued - noted August 8, 2019.
ESKATA (hydrogen peroxide) Seborrheic keratosis (SK) Approved Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2 Common warts (verruca vulgaris) Phase 3 Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-450 Rheumatoid arthritis (RA) Phase 2b Phase 2b trial to be initiated 2H 2021.
ATI-1777-AD-201 Atopic dermatitis Phase 2a Phase 2a data due mid-2021.
ATI-450 COVID-19 Phase 2a Phase 2a dosing commenced August 2020.
$1.40
-0.05  -3.45%
118.9 million
$166.5 million
04/09/2021
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
DSUVIA (ARX-04) Moderate-to-severe acute pain following a surgical procedure Approved FDA Approval announced November 2, 2018.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. NDA resubmission planned.
$0.54
-0.02  -2.85%
96.9 million
$52.2 million
04/09/2021
Tap to view 1 drug
$14.48
-1.36  -8.59%
42.2 million
$610.8 million
04/09/2021
Tap to view 3 drugs
Drug Indication Stage News
ADG106-2001 Solid tumors Phase 2 Phase 2 readout due 2H 2021.
ADG116 Solid Tumors Phase 1 Phase 1 efficacy data due 2H 2021.
ADG126 Solid tumors Phase 1 Phase 1 trial initiation announced March 16, 2021. Safety and efficacy read out in selected indications in 2H 2021.
$5.05
-0.08  -1.56%
155.1 million
$783.4 million
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
MAGE-A4 (ADP-A2M4) Solid tumors Phase 1 Phase 1 update at American Society for Radiation Oncology (ASTRO) October 24-27, 2021.
AFP (ADP-A2AFP) Hepatocellular carcinoma Phase 1 Phase 1 update at International Liver Cancer Association (ILCA) conference September 2-5, 2021.
MAGE-A10 (ADP-A2M10) Non-Small Cell Lung Cancer (NSCLC) Phase 1 Phase 1 enrolment completed 2019.
MAGE-A4 (SPEARHEAD‑1) Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Phase 2 Phase 2 enrolment has been completed. Initial data at ASCO June 4-8, 2021.
MAGE-A4 (ADP-A2M4CD8 - SURPASS) Solid tumors Phase 1 Phase 1 update due at ESMO September 17-21, 2021.
ADP-A2M4CD8 Gastroesophageal cancers Phase 1 Phase 2 trial to commence 1H 2021.
$23.99
-1.83  -7.09%
76.7 million
$1.8 billion
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
Camidanlumab tesirine Hodgkin lymphoma (HL) Phase 2 Phase 2 interim data 1H 2021.
Loncastuximab Tesirine Diffuse Large B-Cell Lymphoma PDUFA priority review PDUFA date under priority review May 21, 2021.
Camidanlumab Tesirine and pembrolizumab Solid Tumors Phase 1b Phase 1b data released at ESMO September 17, 2020.
Loncastuximab Tesirine Follicular Lymphoma Phase 2 Phase 2 pivotal trial to be initiated 1H 2021.
Loncastuximab Tesirine + Ibrutinib (LOTIS-3) Diffuse Large B-Cell or Mantle Cell Lymphoma Phase 1/2 Phase 1/2 updated data due 1H 2021.
Loncastuximab Tesirine and rituximab (LOTIS 5) Diffuse Large B-Cell Lymphoma Phase 3 Phase 3 data due 2H 2021.
$2.38
-0.04  -1.65%
17.3 million
$41.1 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
AD04 Alcohol use disorder Phase 3 Phase 3 data due in 4Q 2021 or earlier.
$1.76
-0.11  -5.88%
121.3 million
$213.4 million
04/09/2021
Tap to view 2 drugs
Drug Indication Stage News
ASCENIV (RI-002) Primary Immune Deficiency Diseases Approved FDA Approval announced April 1, 2019.
BIVIGAM Primary humoral immunodeficiency CRL Response to Complete Response Letter submitted January 7, 2019.
$0.89
-0.06  -6.62%
140.3 million
$124.2 million
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. Approved CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000 Asthma/COPD Phase 2 Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose Anaphylaxis Approved FDA Approval announced September 27, 2018.
ZIMHI (naloxone HCI Injection) Opioid overdose CRL CRL announced November 16, 2020.
APC-8000 (sublingual tadalafil) Erectile dysfunction NDA Filing Refusal to file letter received February 26, 2019.
$4.52
-0.07  -1.53%
43.1 million
$194.7 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
GOCOVRI (amantadine) Multiple sclerosis (MS) Phase 3 Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019. Findings were confirmed June 17, 2020.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
GOCOVRI (ADS-5102) Levodopa-Induced Dyskinesia + Parkinson's disease patients receiving levodopa and experiencing OFF episodes Approved FDA Approval announced August 24, 2017. Second approval to include treatment of OFF episodes in PD patients receiving levodopa announced February 1, 2021.
GOCOVRI (amantadine) Dyskinesia patients with Parkinson's disease Phase 3 Phase 3 open-label data released April 19, 2018.
$40.42
-1.63  -3.88%
139.2 million
$5.6 billion
04/09/2021
Drug Indication Stage News
$2.94
-0.02  -0.68%
14.5 million
$42.6 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
ADi Psoriasis Phase 1/2 Phase 1/2 trial planned.
$9.08
-0.63  -6.49%
97.8 million
$888 million
04/09/2021
Tap to view 2 drugs
Drug Indication Stage News
ADVM-022 Wet age-related macular degeneration (Wet-AMD) Phase 1 Phase 1 long-term data to be presented 2Q 2021. Phase 3 trials to be initiated 4Q 2021.
ADVM-022 - INFINITY Diabetic macular edema Phase 2 Phase 2 data due 2H 2021.
$0.67
-0.04  -5.45%
119.5 million
$79.6 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
ADXS-PSA and Keytruda - KEYNOTE-046 Castrate-resistant prostate cancer Phase 1/2 Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 trial closed - noted June 27, 2019.
ADXS-503 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 data presented at SITC meeting November 2020. Noted October 26, 2020 overall response rate of 17% (1/6 patients). Further data due in 2021.
ADXS-504 Prostate Cancer Phase 1 Phase 1 trial to be initiated 1Q 2021 with initial data due 2H 2021.
$18.83
-0.14  -0.74%
46.9 million
$883.4 million
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
Roclatan Glaucoma Approved FDA Approval announced March 12, 2019.
Rhopressa Glaucoma Approved PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503 Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) Phase 1/2 Phase 1/2 trial initiation announced August 20, 2019.
AR-1105 Macular edema due to RVO (retinal vein occlusion) Phase 2 Phase 2 top-line data July 27, 2020 noted treatment was well tolerated with no unexpected safety findings with sustained treatment effects.
Roclatan - Mercury 3 Open Angle Glaucoma Phase 3 Phase 3 top-line data released September 24, 2020. Non-inferiority to Ganfort achieved.
AR-15512 (AVX-012) - COMET-1 Dry eye disease Phase 2b Phase 2b top-line data due 3Q 2021.
$1.10
+0.01  +0.92%
121.1 million
$133.2 million
04/09/2021
Tap to view 3 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Approved CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
Macimorelin acetate (AEZS-130) Paediatric patients with suspected growth hormone deficiency (GHD) Phase 3 Phase 3 trial to commence 2Q 2021.
$9.74
+1.85  +23.45%
114.8 million
$1.1 billion
04/09/2021
Tap to view 8 drugs
Drug Indication Stage News
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 (REDIRECT) CD30-positive peripheral T cell lymphoma (PTCL) Phase 2 Phase 2 enrollment to continue as planned following futility analysis - March 10, 2021.
AFM11 Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 program terminated - noted May 22, 2019.
AFM24 EGFR-expressing solid tumors Phase 1/2 Phase 1/2a cohort 3 has completed dosing.
AFM13 + NK cells CD30-positive lymphomas Phase 1 Phase 1 early data to be presented at AACR meeting April 13, 2021 at 1:30pm ET. Data released April 9, 2021 noted 100% response rate (2/4 partial responses and 2/4 complete responses).
AFM13 T-Cell, Cutaneous Lymphoma Phase 1/2 Phase 1/2 data presented at ASH 2020. Objective Response Rate (ORR) of 42%(6/14).
AFM24 and Tecentriq EGFR Expressing Solid Tumors Phase 1/2 Phase 1/2 trial planned.
AFM24/SNK-01 EGFR-expressing tumors Phase 1/2 Phase 1/2 trial planned.
$52.77
-0.15  -0.28%
69.6 million
$3.7 billion
04/09/2021
Tap to view 13 drugs
Drug Indication Stage News
AG-348 - Mitapivat Thalassemia Phase 2 Phase 2 updated data at EHA June 12, 2020. Primary endpoint defined as a ≥1.0 g/dL increase in Hb concentration from baseline at 1 or more assessments between week 4 and week 12 was met by 12 of 13 (92.3%) patients.
Ivosidenib IDH1m Relapsed/Refractory AML - cancer Approved FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE-T) Pyruvate kinase deficiency Phase 3 Phase 3 trial met primary endpoint - January 26, 2021. Data to be presented at EHA Virtual Congress, June 9-17, 2021
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 enrolment to be completed 2021.
IDHIFA (enasidenib) - AG-221 Advanced hematologic malignancies with an IDH2 mutation Approved Approval announced August 1, 2017.
Ivosidenib (ClarIDHy) IDH1 mutant cholangiocarcinoma - cancer sNDA Filing sNDA filing announced March 1, 2021.
AG-270 Solid tumors Phase 1 Phase 1 enrolment has slowed due to COVID-19. A go/no-go decision is expected no later than 2022.
Vorasidenib (AG-881) Glioma Phase 3 Phase 3 enrolment has slowed as a result of COVID-19.
Ivosidenib Frontline AML with IDH1 mutation Approved FDA Approval announced May 2, 2019.
Vorasidenib (AG-881) IDHm low-grade glioma Phase 1 Phase 1 presentation at ASCO May 29, 2020. Median Progression-free Survival of 31.4 months.
AG-348 - Mitapivat (ACTIVATE) Pyruvate Kinase Deficiency Phase 3 Phase 3 trial met primary endpoint - December 1, 2020. Data to be presented at EHA Virtual Congress, June 9-17, 2021
AG-348 - Mitapivat Sickle cell disease. Phase 2/3 Phase 2/3 trial to be initiated by end of 2021.
AG-946 Healthy volunteers Phase 1 Phase 1 data to be presented by end of 2021.
$7.71
+0.03  +0.39%
48 million
$370.2 million
04/09/2021
Tap to view 2 drugs
Drug Indication Stage News
Pegzilarginase (AEB1102) - PEACE Arginase I deficiency Phase 3 Phase 3 data due 4Q 2021.
ACN00177 Homocystinuria Phase 1/2 Phase 1/2 trial initiated June 2020.
$1.97
-0.02  -1.01%
87.6 million
$172.6 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch Approved FDA Approval announced February 14, 2020.
$4.41
-0.16  -3.50%
42.8 million
$188.5 million
04/09/2021
Tap to view 3 drugs
$2.25
-0.03  -1.32%
39.7 million
$89.3 million
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
Ampligen CFS CRL CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 All patients have been treated or are near completion of treatment - August 2020.
Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Phase 2 trial ongoing.
Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 Phase 2 trial is enrolling - noted August 2020.
Ampligen, Intron A Prostate Cancer Phase 2 Phase 2 trial has been initiated - noted August 2020.
Ampligen and interferon alpha-2b COVID-19 Phase 1/2 Phase 1/2a trial commencement of dosing announced November 25, 2020.
$3.06
-0.1  -3.16%
153.5 million
$469.7 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
Auryxia Hyperphosphatemia Approved Approved Sept 5, 2014.
Vadadustat Anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis. NDA Filing NDA filing announced March 30, 2021.
Auryxia Iron deficiency anemia in non-dialysis dependent CKD patients Approved sNDA FDA Approval announced November 7, 2017.
Vadadustat COVID-19 Phase 3 Phase 3 initiation announced July 14, 2020.
$3.21
-0.11  -3.31%
16.7 million
$53.5 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
VLP vaccine COVID-19 vaccine Phase 1 Pre-clinical trials are planned with clinical trials to be potentially initiated after.
$27.76
-0.52  -1.84%
34.8 million
$965.2 million
04/09/2021
Tap to view 2 drugs
$2.41
-0.14  -5.49%
38.5 million
$92.7 million
04/09/2021
Tap to view 5 drugs
$13.87
-0.19  -1.35%
34.4 million
$477.2 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
AK-OTOF Hearing loss Phase 1/2 Phase 1/2 IND filing to be submitted 1H 2022.
$32.88
-0.8  -2.38%
19.1 million
$628.5 million
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
Odevixibat Progressive familial intrahepatic cholestasis (PFIC) PDUFA priority review PDUFA date under priority review July 20, 2021.
Elobixibat Nonalcoholic steatohepatitis (NASH) Phase 2 Phase 2 trial met primary endpoint. However, development in NASH will not continue - August 18, 2020.
Odevixibat (A4250) Biliary atresia Phase 3 Phase 3 commencement of enrolment announced July 14, 2020. Data due 2024.
Odevixibat (ASSERT) Alagille syndrome Phase 3 Phase 3 data due 2022.
A3907 Liver disease Phase 1 Phase 1 top-line data due 2H 2021.
$12.04
-0.49  -3.91%
47.2 million
$568.9 million
04/09/2021
Tap to view 8 drugs
Drug Indication Stage News
Reproxalap (TRANQUILITY) Dry eye syndrome Phase 3 Phase 3 data due 2H 2021.
Reproxalap (INVIGORATE) Allergic conjunctivitis Phase 3 Phase 3 data due 2Q 2021.
ADX-102 reproxalap Noninfectious anterior uveitis Phase 3 Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102) Sjögren-Larsson Syndrome (SLS) Phase 3 Development placed on hold - noted March 12, 2020.
ADX-1612 (ganetespib) Post-transplant lymphoproliferative disorder Phase 2 Development placed on hold - noted March 12, 2020.
ADX-2191 Proliferative vitreoretinopathy (PVR) Phase 3 Phase 3 (Part 1) completion of enrollment due 2021.
ADX-629 Psoriasis / atopic asthma / COVID-19 Phase 2 Phase 2 top-line data due by the end of 2021.
ADX-1612 Ovarian cancer Phase 2 Phase 2 trial ongoing.
$17.37
-2.26  -11.51%
79.6 million
$1.4 billion
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
AL001 (INFRONT-3) Frontotemporal Dementia Phase 3 Phase 3 commencement of dosing announced July 24, 2020.
AL002 (INVOKE-2) Alzheimer’s disease Phase 2 Phase 2 initiation of dosing announced January 25, 2021.
AL003 Alzheimer’s disease Phase 1 Phase 1b data due 2021.
AL101 Healthy volunteers Phase 1a Phase 1a data due in 2021.
AL001 (INFRONT-2) Frontotemporal Dementia Phase 2 Phase 2 open-label additional data due 2021.
AL001 Amyotrophic lateral sclerosis (ALS) Phase 2 Phase 2 trial planned for 2021.
$21.47
+1.17  +5.76%
38.1 million
$818.9 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
ALG-010133 Hepatitis B Phase 1 Phase 1 safety and antiviral data from the initial cohort(s) is expected in 2H 2021.
ALG-000184 Hepatitis B Phase 1 Phase 1 safety and antiviral data from the initial cohort(s) expected in 2H 2021.
ALG-020572 Hepatitis B Phase 1 Phase 1 trial to commence 2H 2021.
ALG-055009 Nonalcoholic steatohepatitis (NASH) Phase 1 Phase 1 trial to commence 1H 2021.
$9.56
+0.14  +1.49%
5.8 million
$55 million
04/09/2021
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$19.02
-0.03  -0.16%
159.2 million
$3 billion
04/09/2021
Tap to view 12 drugs
Drug Indication Stage News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) Schizophrenia Approved FDA approval announced July 2, 2018.
ALKS 3831 (olanzapine/samidorphan) Schizophrenia, bipolar PDUFA priority review CRL announced November 17, 2020. New PDUFA date June 1, 2021.
BYDUREON Type 2 diabetes Approved CRL received March 15, 2010.
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098) Multiple sclerosis (MS) Approved FDA Approval announced October 30, 2019.
ALKS 5461 Major depressive disorder CRL CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1 Schizophrenia Phase 3 Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1 Solid tumors Phase 1 Phase 1/2 data presented at ESMO September 18, 2020. 1/5 partial responses in melanoma cohort (monotherapy).
Aristada and Invega Sustenna Schizophrenia Phase 3 Phase 3 data released April 9, 2019 - primary endpoint met.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - Relapsing Remitting Multiple Sclerosis (RRMS) Phase 3 Phase 3 top-line data met primary endpoint - July 30, 2019.
ALKS 4230 (ARTISTRY-3) Solid Tumors Phase 3 Phase 2 trial initiation announced August 18, 2020.
Nemvaleukin (ALKS 4230) Ovarian cancer Phase 3 Phase 3 trial to commence 2H 2021.
$105.00
-3  -2.78%
53.1 million
$5.6 billion
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
AK002 Severe Allergic Conjunctivitis Phase 1b Phase 1b presentation at ASCRS May 16, 2020.
Lirentelimab Eosinophilic Gastritis Phase 3 Phase 3 top-line data due 4Q 2021.
Lirentelimab Eosinophilic esophagitis Phase 2/3 Phase 2/3 top-line data due 4Q 2021.
Lirentelimab (subcutaneous) Eosinophilic gastritis (EG) / eosinophilic duodenitis (EoD) Phase 2/3 Phase 2/3 trial to be initiated 2H 2021.
Lirentelimab Eosinophilic duodenitis (EoD) Phase 3 Phase 3 trial to be initiated 2Q 2021.
$32.82
-0.83  -2.47%
140.6 million
$4.6 billion
04/09/2021
Tap to view 8 drugs
Drug Indication Stage News
UCART19 (PALL) Acute lymphoblastic leukemia (ALL) Phase 1 Phase 1 trial ongoing.
UCART19 - CALM Refractory B-cell Acute Lymphoblastic Leukaemia Phase 1 Phase 1 trial ongoing.
ALLO-715 - UNIVERSAL Multiple myeloma Phase 1/2 Phase 1/2 data presented at ASH December 5, 2020. DL3 cohort (320M CAR T+ cells) overall response rate (ORR) was 60%.
ALLO-501 - ALPHA Non-Hodgkin lymphoma (NHL) Phase 1 Phase 1 further data due 2Q 2021.
ALLO-715 with nirogacestat Multiple myeloma Phase 1 Phase 1 enrollment has been initiated - February 25, 2021.
ALLO-501A (ALPHA2) Large B-cell lymphoma Phase 1 Phase 1 initial data due 2Q 2021.
ALLO-316 - TRAVERSE Clear cell renal cell carcinoma (ccRCC) Phase 1 Phase 1 trial to be initiated 1Q 2021.
AUTO8 Multiple Myeloma Phase 1 Phase 1 trial to commence mid-2021.
$1.30
-0.04  -2.99%
56.9 million
$73.9 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
Reloxaliase ALLN-177 (URIROX-1) Enteric Hyperoxaluria Phase 3 Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (Study 206) Primary hyperoxaluria Phase 2 Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (URIROX-2) Enteric Hyperoxaluria Phase 3 Phase 3 interim analysis due 2Q/3Q 2022 and top-line data late-2022 or early-2023.
ALLN-346 Hyperuricemia Phase 1/2 Phase 1b multiple-ascending dose trial in healthy volunteers to be initiated 2Q 2021, with initial data due 3Q 2021.
$138.23
-4.27  -3.00%
117.3 million
$16.2 billion
04/09/2021
Tap to view 15 drugs
Drug Indication Stage News
Givosiran Acute hepatic porphyrias Approved FDA approval announced November 20, 2019.
Inclisiran Hypercholesterolemia NDA Filing CRL received December 18, 2020. NDA to be refiled 2Q/3Q 2021.
VIR-2218 Chronic hepatitis B virus (HBV) Phase 2 Phase 2 initial data due 2021.
Lumasiran Primary Hyperoxaluria Type 1 (PH1) Approved FDA approval announced November 24, 2020.
Patisiran Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Approved FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran) IgA nephropathy Phase 2 Phase 2 top-line data due 2021.
Fitusiran (ATLAS) Hemophilia A/B Phase 3 Phase 3 top-line data due 2H 2021.
Vutrisiran - HELIOS-A ATTR amyloidosis Phase 3 Phase 3 9-month data to be presented at AAN meeting April 19, 2021 at 2:00 pm ET.
ALN-AAT02 alpha-1 anti-trypsin deficiency-associated liver disease Phase 1/2 Phase 1/2 initial data released.
Lumasiran (ALN-GO1) ILLUMINATE-B Primary Hyperoxaluria Type 1 Phase 3 Phase 3 top-line released September 30, 2020.
Patisiran APOLLO-B Wild-type ATTR amyloidosis patients with cardiomyopathy Phase 3 Phase 3 enrolment to be completed early-2021.
Lumasiran (ALN-GO1) ILLUMINATE-C Impaired renal function Phase 3 Phase 3 top-line data due mid-2021.
ALN-TTRsc02 (vutrisiran) - HELIOS-B ATTR amyloidosis with cardiomyopathy Phase 3 Phase 3 trial has been initiated - noted November 22, 2019.
VIR-2703 / ALN-COV COVID-19 Phase 1 IND filing has been delayed - announced November 5, 2020.
IR-2218 with pegylated interferon-alpha (PEG-IFN-α) Hepatitis B Phase 2 Phase 2 initial data due 2021
$11.33
+0.13  +1.16%
23.9 million
$270.6 million
04/09/2021
Tap to view 3 drugs
Drug Indication Stage News
N91115 Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein Phase 2 Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-202 Advanced Malignancies Phase 1 Phase 1 initiation of dosing announced June 24, 2020.
ALPN-101 Graft Vs Host Disease Phase 1/2 Phase 1b/2 trial is open for enrolment - noted March 30, 2020.
$1.34
-0.08  -5.63%
90.2 million
$120.9 million
04/09/2021
Tap to view 4 drugs
Drug Indication Stage News
ALRN-6924 and Cytarabine (Ara-C) Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) Phase 1b Phase 1/1b trial ongoing.
ALRN-6924 and Paclitaxel Breast cancer Phase 1 Phase 1 has been initiated.
ALRN-6924 Small Cell Lung Cancer (SCLC) Phase 1b Phase 1b/2 final data to be presented 2H 2021.
ALRN-6924 Non-small cell lung cancer Phase 1b Phase 1b enrollment to commence 2Q 2021 with initial results due 4Q 2021 and full results mid-2022.
$12.90
-0.22  -1.68%
37.2 million
$479.2 million
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
HepTCell Hepatitis B Phase 2 Phase 2 commencement of enrollment announced December 30, 2020. Data due 1H 2022.
NasoVAX Flu vaccine Phase 2 Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD Anthrax Phase 1b Phase 1b data released April 1, 2021.
ALT-801 Non-alcoholic steatohepatitis (NASH) Phase 1 Phase 1 6-week MAD data due 2Q 2021.
AdCOVID COVID-19 vaccine Phase 1 Phase 1 data due 2Q 2021.
T-COVID COVID-19 Phase 1/2 Phase 1/2 data due 2Q 2021.
$23.21
-1.2  -4.92%
62.7 million
$1.5 billion
04/09/2021
Tap to view 7 drugs
Drug Indication Stage News
ALVR105 Multi-virus prevention trial Phase 2 Phase 2 initial data from open-label phase due 2H 2021.
ALVR109 COVID-19 Phase 1/2 Phase 1/2 top-line data due 2H 2021.
Viralym-M (ALVR105) BK virus Phase 2 Phase 2 interim data due 2H 2021.
Viralym-M (ALVR105) Cytomegalovirus (CMV) Phase 2 Phase 2 trial to be initiated in 2021.
Viralym-M (ALVR105) Aleution disease virus (ADV) Phase 2 Phase 2 trial to be initiated in 2021.
Viralym-M (ALVR105) Cytomegalovirus (CMV) Phase 2 Phase 2 trial to be initiated.
Viralym-M (ALVR105) Virus-associated hemorrhagic cystitis Phase 3 Phase 3 trial has been initiated.
$155.01
+0.54  +0.35%
219.8 million
$34.1 billion
04/09/2021
Tap to view 26 drugs
Drug Indication Stage News
CAEL‐101 AL amyloidosis Phase 3 Phase 3 top-line data due 2H 2022.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Approved FDA Approval announced June 27, 2019.
ULTOMIRIS (ravulizumab-cwvz) atypical Hemolytic Uremic Syndrome (aHUS) Approved FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz) Paroxysmal nocturnal hemoglobinuria (PNH) Approved FDA approval announced December 21, 2018.
Eculizumab Refractory generalized myasthenia gravis (gMG) Approved Approval announced October 23, 2017.
Bevyxxa (betrixaban) Venous thromboembolism (VTE) Prevention Approved FDA Approval noted June 23, 2017.
Cerdulatinib (PRT2070) Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer Phase 2 Phase 2a data presented at ASH December 9, 2019. ORR 48%; 76% in combo cohort.
Andexxa Factor Xa inhibitor reversal agent Approved Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
ALXN2040 add-on therapy Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 data due 2H 2022.
ALXN2050 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 trial has been paused pending further data from Phase 1 trial.
AG10 / BBP-265 ATTR-PN Phase 2 Phase 3 trial has been initiated.
ALXN1840 (WTX101) Wilson disease Phase 3 Phase 3 top-line data due 1H 2021.
ULTOMIRIS (ravulizumab-cwvz) Generalized myasthenia gravis (gMG) Phase 3 Phase 3 top-line data due 2H 2021.
ALXN1830 Warm autoimmune hemolytic anemia (WAIHA) Phase 1/2 Phase 2/3 trial to be initiated 2H 2021.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 trial met primary endpoint - June 24, 2020. Regulatory filing due 3Q 2021.
Elamipretide Leber’s hereditary optic neuropathy (LHON) Phase 2 Phase 2 trial did not meet primary endpoint.
ULTOMIRIS Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Phase 3 Phase 3 trial initiated 4Q 2020.
Eculizumab Generalized myasthenia gravis (gMG) - children Phase 3 Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab Neuromyelitis Optica Spectrum Disorder (NMOSD) - children Phase 2/3 Phase 2/3 trial underway.
ULTOMIRIS (ravulizumab) - CHAMPION-ALS Amyotrophic lateral sclerosis (ALS) Phase 3 Phase 3 top-line data due 2H 2022.
ULTOMIRIS (ravulizumab-cwvz) COVID-19 Coronavirus Phase 3 Independent data monitoring committee recommended pausing enrollment due to lack of efficacy in pre-specified interim analysis - January 13, 2021.
ALXN2040 C3 Glomerulopathy (C3G) Phase 2 Development discontinued - noted July 29, 2020.
ULTOMIRIS Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 data top-line data due 2H 2022.
ULTOMIRIS Dermatomyositis (DM) Phase 2/3 Phase 2/3 trial to be initiated 2H 2021.
ALXN2040 Geographic Atrophy (GA) Phase 2 Phase 2 trial to be initiated 2H 2021.
ALXN2040 COVID-19 Phase 2 Phase 2 trial has been initiated.
$63.77
-8.41  -11.65%
40.1 million
$2.6 billion
04/09/2021
Tap to view 5 drugs
Drug Indication Stage News
ALX148 and azacitidine (ASPEN-02) Myelodysplastic syndromes (MDS) Phase 1 Phase 1 data and Phase 2 initiation due 4Q 2021.
ALX148 and Keytruda (ASPEN-03 and ASPEN-04) Head and neck squamous cell carcinoma (HNSCC) Phase 2 Phase 2 trial to be initiated 1H 2021.
ALX148 and trastuzumab (Herceptin) - (ASPEN-01) Solid Tumors and Lymphoma Phase 1 Phase 1 full data to be presented mid-2021.
ALX148 in combination with azacitidine and venetoclax (ASPEN-05) Acute myeloid leukemia (AML) Phase 1 Phase 1 trial to be initiated 2H 2021.
ALX148 + Herceptin (trastuzumab) + Cyramza ramucirumab and paclitaxel (ASPEN-06) 2nd line or greater gastric/gastroesophageal junction cancer Phase 2 Phase 2 trial to be initiated 2H 2021.
$13.75
  +0.00%
34.7 million
$477.5 million
04/09/2021
Tap to view 6 drugs
Drug Indication Stage News
AMAG-423 / Digoxin immune fab (DIF) Severe preeclampsia in pregnant women Phase 2/3 Phase 2/3 trial stopped due to low likelihood of efficacy - August 6, 2020.
Vyleesi (Bremelanotide) Female sexual dysfunction (FSD) Approved FDA approval announced June 21, 2019.
Feraheme Adults with iron deficiency anemia (IDA) Approved Approval for sNDA filing announced February 5, 2018.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approval announced February 14, 2018.
Makena Preterm birth Phase 3 Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Ciraparantag Anticoagulated reversal agent / Healthy volunteers Phase 2 Phase 2b trial planned.
AMGN Amgen Inc.
$248.95
+2.07  +0.84%
575.8 million
$143.3 billion
04/09/2021
Tap to view 43 drugs
Drug Indication Stage News
Tezepelumab - NAVIGATOR Asthma Phase 3 Phase 3 trial met primary endpoint - November 10, 2020.
Prolia (denosumab) Glucocorticoid-induced osteoporosis (GIOP) Approved Approval announced May 21, 2018.
KYPROLIS (ASPIRE) Relapsed Multiple Myeloma Approved sNDA approval announced June 11, 2018.
Vectibix (Panitumumab) Wild-Type RAS Metastatic Colorectal Cancer Approved sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb) Biosimilar candidate to Avastin (bevacizumab) Approved Approved September 14, 2017.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine Approved Approval announced May 17, 2018.
OTEZLA Scalp Psoriasis Approved FDA approval announced April 2020.
OTEZLA - PSA-006 Psoriatic Arthritis Phase 3 Phase 3 - primary endpoint met.
OTEZLA Behçet’s Disease Approved FDA Approval announced July 19, 2019.
Repatha Cardiovascular disease Approved Approval announced December 1, 2017.
XGEVA Multiple Myeloma Approved sBLA approval announced January 5, 2017.
KYPROLIS (ARROW) Multiple Myeloma Approved FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Approved sNDA approved January 17, 2018.
BLINCYTO Ph+ R/R ALL Approved PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
RIABNI (rituximab-arrx) RITUXAN biosimilar - non-Hodgkin lymphoma Approved FDA approval announced December 17, 2020.
ABP 980 (Kanjinti; trastuzumab-anns) Herceptin biosimilar CRL FDA approval announced June 13, 2019.
ABP 710 REMICADE biosimilar - rheumatoid arthritis Approved FDA Approval announced December 6, 2019.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
EVENITY (Romosozumab) Osteoporosis Approved FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 top-line data met primary composite endpoint of reduction in cardiovascular death or heart failure but did not meet secondary endpoint of reduction in cardiovascular death - October 8, 2020.
Omecamtiv mecarbil METEORIC-HF Acute heart failure Phase 3 Phase 3 enrollment to be completed 1H 2021.
AMG 420 Relapsed. Refractory (R/R) Multiple Myeloma (MM) Phase 1 Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
Nplate (Romiplostim) Immune Thrombocytopenia (Pediatric) Approved FDA approval announced December 14, 2018.
Nplate (Romiplostim) Immune thrombocytopenia (ITP) Approved FDA Approval announced October 18, 2019.
OTEZLA Plaque psoriasis sNDA Filing sNDA filing announced February 22, 2021.
CK-136 (AMG 594) Healthy volunteers Phase 1 Phase 1 trial has been completed.
AMG 510 Solid tumors Phase 1 Phase 1 update at ASCO May 29, 2020. Objective response rate (ORR) was 12% (3/25) in 960 mg once-daily target dose cohort.
CNP520 Alzheimer’s Disease Phase 2/3 Phase 2/3 trial discontinued due to lack of efficacy.
BLINCYTO Acute lymphoblastic leukemia (ALL) - pediatric Phase 3 Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
AMG 570 Systemic Lupus Erythematosus (SLE) Phase 2 Phase 2 trial is enrolling.
Tezepelumab Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trial is enrolling.
AMG 510 - sotorasib (CodeBreak 100) Non-small cell lung cancer (NSCLC) PDUFA priority review PDUFA date under priority review August 16, 2021.
AMG 510 CodeBreaK 200 Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 trial is enrolling.
AMG 890 Cardiovascular disease / Elevated Lipoprotein Phase 2 Phase 2 trial has commenced - noted July 28, 2020.
AMG 592 Systemic Lupus Erythematosus Phase 1/2 Phase 1b/2 trial is enrolling - noted July 28, 2020.
Efavaleukin alfa (AMG 592) Chronic Graft Versus Host Disease Phase 1/2 Phase 1b/2 trial is enrolling - noted July 28, 2020.
AMG 701 Multiple Myeloma Phase 1 Phase 1 enrollment has been paused to discuss changes to safety monitoring and mitigation, expects to resume patient enrollment in 1H 2021.